GLP-1 receptor agonists
PBAC accused of ‘lack of ambition’
Manufacturers of GLP-1 medications are stepping up pressure on the federal government to subsidise their products for weight loss Sponsors of glucagon-like peptide-1 (GLP-1) medications are accusing the Pharmaceutical Benefits Advisory Committee …
Cost ‘major barrier’ to access, patients lowering doses
Resounding support for subsidising GLP-1s for obesity treatment, PBS public consultation submissions show, with quality of medicines issues present Submissions from 491 consumers, 25 health professionals and 23 organisations to …
Weight loss drugs added to WADA’s watchlist
GLP-1s could be added to the World Anti-Doping Agency’s prohibited list before the 2028 Olympics Over the next two years, the World Anti-Doping Agency (WADA) is set to review whether use of glucagon-like peptide-1 medications gives …
TGA issues fake GLP-1 warning
Testing confirms imported unregistered GLP-1 weight loss products are not what they claim to be Consumers are being urged to avoid purchasing online medicines claiming to contain glucagon-like peptide-1s (GLP-1s), warning …
‘Concerning’: Low levels of contraception alongside GLP-1 use
Off-label use of GLP-1s among women of reproductive age has skyrocketed since 2020, with researchers concerned about its potential impact on unintended pregnancies Community pharmacists have an opportunity to counsel …
Inquiry backs expansion of GLP-1 RA eligibility
Government urged to make Glucagon-like Peptide-1 receptor agonists (GLP-1 RAs) available to more patients Steps to improve access to GLP-1 RAs for high-risk patients are among 23 recommendations in the …